Jones Financial Companies
RGC icon

Jones Financial Companies’s Regencell Bioscience RGC Stock Holding History

Jones Financial Companies’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$642 Buy
+99
New +$2.38K ﹤0.01% 4706

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Jones Financial Companies's RGC Position: Q2 2026 in Review

Jones Financial Companies opened a new position in Regencell Bioscience (RGC) in Q2 2026: 99 shares worth $642. The stake represents ﹤0.01% of the portfolio and ranks #4706 among its holdings.

35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Jones Financial Companies held 99 shares of Regencell Bioscience worth $642 as of Q2 2026.
  • Regencell Bioscience was a new Jones Financial Companies position in Q2 2026.
  • Regencell Bioscience made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4706 holding.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.